Clinical Application of a Brain Image Analysis Program for Multiple Sclerosis Part 3 Clinical Significance of Brain Volume Visualization

Microns-ViewPoint-White-Paper

We would like to share the third article, the final article in the series by Dr. Kenzo Sakurai of St. Marianna University School of Medicine titled: “Clinical Significance of ‘Brain Volume Visualization’: A Treatment Strategy for Long-Term Prognosis” from the series “Clinical Application of a Brain Image Analysis Program for Multiple Sclerosis.”

In this article, there is a discussion how to apply a brain imaging analysis program to actual clinical practice. We hope that you will enjoy it.

Note: This white paper is an English translation of the Japanese version (MVP15, published on Jun 28, 2021). The information reflects the content as of the original publication date.

Micron’s ViewPoint No.15 (Issued: Apr 20, 2022)

What is “Micron’s ViewPoint”?

“Micron’s ViewPoint” is a white paper series published by Micron, sharing expert insights on imaging, pharmaceutical and medical device development, and clinical trials.

The series covers a wide range of topics, including image assessment and analysis, Software as a Medical Device (SaMD), and theranostics, providing practical and valuable information for professionals involved in pharmaceutical and medical device development.

View More of Micron’s ViewPoint>

This field is for validation purposes and should be left unchanged.
*If you have set up domain rejection, please check your email receiving settings to allow emails from [@micron-kobe.com].
Micron Updates
ConfirmationRequired

Please feel free to contact us

We provide comprehensive, end‑to‑end clinical development support, with imaging at its core.

With more than 20 years of experience, our team of imaging specialists in Japan and around the world tackles the complex challenges of imaging evaluation in pharmaceutical and medical device development. We deliver optimal, project‑specific solutions for each client.